secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sight Sciences, Inc. (SGHT)
CIK:        0001531177
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066935
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sight Sciences Q1 revenue $17.5M (-9% YoY); reaffirms FY25 guidance $70-75M; lowers expense guide
--------------------------------------------------------------------------------

- Total revenue $17.5M, down 9% YoY; Surgical Glaucoma $17.1M (-6% YoY); Dry Eye $0.4M (-60% YoY).
- Gross margin 86% flat YoY; net loss $14.2M ($0.28 loss per share) vs $16.3M loss in prior year.
- Reaffirms FY25 revenue guidance $70-75M (decline 6-12% YoY); lowers adjusted op ex guide to $101-105M.
- Tariffs on China-made products seen adding $3.5-4.5M to 2025 COGS; impact larger in H2 2025.
- Launched OMNI Edge with TruSync technology at ASCRS April 2025; TearCare reimbursement not assumed in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1531177/000095017025066935/0000950170-25-066935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1531177/000095017025066935/sght-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer